UMRX stock forecast
Our latest prediction for Unum Therapeutics, Inc.'s stock price was made on the April 3, 2018 when the stock price was at 10.75$.
In the short term (2weeks), UMRX's stock price should outperform the market by 3.62%. During that period the price should oscillate between -2.63% and +4.01%.
In the medium term (3months), UMRX's stock price should outperform the market by 7.80%. During that period the price should oscillate between -5.96% and +12.42%.Get email alerts
About Unum Therapeutics, Inc.
Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.
At the moment the company generates 8M USD in revenues.
On its last earning announcement, the company reported a loss of -1.09$ per share.
The book value per share is 2.57$
Three months stock forecastApril 3, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|